Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Shares Outstanding (Diluted Average) (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Shares Outstanding (Diluted Average) for 15 consecutive years, with $102.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) fell 1.16% year-over-year to $102.5 million, compared with a TTM value of $102.5 million through Dec 2025, down 1.16%, and an annual FY2025 reading of $102.5 million, down 1.16% over the prior year.
  • Shares Outstanding (Diluted Average) was $102.5 million for Q4 2025 at Neurocrine Biosciences, roughly flat from $102.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $104.3 million in Q3 2024 and bottomed at $97.1 million in Q1 2023.
  • Average Shares Outstanding (Diluted Average) over 4 years is $101.1 million, with a median of $101.8 million recorded in 2025.
  • The sharpest move saw Shares Outstanding (Diluted Average) rose 6.69% in 2024, then fell 2.21% in 2025.
  • Year by year, Shares Outstanding (Diluted Average) stood at $97.7 million in 2021, then rose by 3.38% to $101.0 million in 2023, then grew by 2.67% to $103.7 million in 2024, then dropped by 1.16% to $102.5 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for NBIX at $102.5 million in Q4 2025, $102.0 million in Q3 2025, and $101.8 million in Q2 2025.